Skip to main content
    White printer paper in San Diego, California

    Can a Lawyer Check If I Qualify for an MDL in San Diego?

    Free consultation with Ronald B. Laba. Call (760) 940-6231.

    Ronald B. LabaNovember 20, 2026
    Google Reviews
    5.0
    157 reviews

    “The Law office of Ronald B. Laba have helped me navigate the justice system through providing detailed explanations of the journey of the lawsuit Ron is helping through. Ron has always communicating what’s going on with my lawsuit step by step with my case made me feel at easy through a very difficult time assuring me that everything will be fine not to lose faith. I appreciate Ron and his team for being there for me and my family I would highly recommend Ron’s law firm”

    AH

    Anthony Hanna

    11 months ago

    By Ronald B. Laba, California attorney (State Bar No. 115846) · Updated November 20, 2026

    Reviewed by Ronald B. Laba, Attorney (Cal Bar 115846) on November 20, 2026

    Short answer

    We can begin by reviewing your medication history, reported injuries, and available records, even if you are unsure whether you have a claim. Our office can identify questions requiring further investigation, review California filing deadlines, and discuss what additional information we would need to assess a particular MDL.

    Key takeaways

    • We start with your concerns and available records rather than asking you to determine whether you qualify before contacting us.
    • We review the medication name, manufacturer, dates of use, symptoms, diagnoses, and treatment history.
    • We distinguish a preliminary claim review from a determination about a particular MDL.
    • We consider California prescription-drug warning claims under Carlin v. Superior Court (1996) 13 Cal.4th 1104.
    • We review timing under CCP 335.1 and the discovery principles explained in Norgart v. Upjohn Co. (1999) 21 Cal.4th 383.
    • We offer a free consultation at (760) 940-6231 to discuss your concerns and possible next steps.

    How We Begin When You Are Unsure You Have a Claim

    We can begin with your questions rather than a conclusion about whether you qualify for a particular MDL. Perhaps you recognize a medication mentioned in a lawsuit but do not know whether your diagnosis is related. Perhaps you experienced symptoms during treatment and never received a clear explanation. Our initial conversation focuses on what happened to you, what information you already have, and what we would need to investigate.

    We start by asking which medication you took, why it was prescribed, and what health problem prompted your concern. We also ask what led you to contact us now: a conversation with your physician, a new diagnosis, a notice, or something you read. These details help us separate your personal medical history from the allegations you may have encountered elsewhere.

    Our preliminary questions may include:

    • What is the medication’s name, and do you still have its packaging?
    • Approximately when did you begin and end treatment?
    • What symptoms or diagnosis are you concerned about?
    • Has a treating clinician discussed a possible connection?
    • Do you have the name or identifying number of the litigation you heard about?

    We do not expect you to arrive with a complete medical file or an explanation of the science. If dates are uncertain, we can start with estimates clearly identified as estimates. If several medications were involved, we want to hear about all of them rather than focus prematurely on one.

    California recognizes prescription-drug failure-to-warn claims involving known or reasonably scientifically knowable dangerous propensities. That principle comes from Carlin v. Superior Court (1996) 13 Cal.4th 1104. We use it as a starting point for investigating an appropriate warning-related claim, not as a conclusion that your medication caused your injury.

    Our goal at this stage is a useful next step. We may identify records to obtain, questions needing medical clarification, or litigation documents requiring review. We distinguish between having enough information to investigate and having enough information to offer an assessment of your potential claim.

    What We Would Need to Investigate a Particular MDL

    When you ask about a particular MDL, we first want to identify the proceeding you mean. A drug name in an advertisement or news story is a starting point, but we would not use that alone to tell you that your circumstances fit. We would compare your information with the actual litigation documents before offering an assessment.

    If available, we ask you to share the proceeding’s name, identifying number, or a copy of the notice that caught your attention. A saved link or screenshot can also help us locate the matter you are referring to. We would then seek the relevant current court documents rather than rely on a summary that may omit important distinctions.

    Our investigation would focus on questions such as:

    • Which medications, formulations, and manufacturers are identified in the proceeding?
    • What injuries and factual allegations appear in the pleadings?
    • What do the current orders say about the proceeding’s scope and procedures?
    • What information would we need to compare your treatment history with those allegations?
    • Are there unresolved questions about product identification or the timing of your injury?

    These are investigative questions, not a universal eligibility checklist. Without reviewing the documents for the identified proceeding, we would not state that a particular diagnosis, treatment duration, or purchase date qualifies you or excludes you.

    For example, you might remember the brand name discussed in a news report while your pharmacy records identify a different manufacturer. We would investigate that discrepancy rather than assume the products are interchangeable for our legal review. Similarly, a broad description of an injury might not match the diagnosis recorded by your treating physician.

    We would also examine your potential California claim separately from the question of how it relates to the identified litigation. Our review should explain what we have verified, which documents remain missing, and what questions remain open. We would not treat your San Diego County address, an advertisement, or a shared medication name as a substitute for that individualized investigation.

    Which Medication and Medical Records Help Our Review

    We find it helpful to begin with records that answer two basic questions: what product did you actually take, and what happened medically? You do not need to organize everything perfectly before contacting us. A prescription label and a recent visit summary may provide a more useful starting point than a lengthy account assembled from memory.

    For medication identification, we ask you to preserve available containers, labels, packaging, and patient information sheets. Clear photographs can help us read details without relying on recollection. Pharmacy dispensing records may help us investigate the product supplied over time, particularly if its appearance or manufacturer changed between refills.

    Our initial records checklist includes:

    • Medication information: prescription labels, dosage instructions, refill histories, and available manufacturer or product identifiers.
    • Prescribing records: notes explaining why treatment began and documenting later changes.
    • Medical findings: diagnosis summaries, laboratory results, imaging reports, and relevant procedure records.
    • Treatment history: visit notes addressing symptoms, referrals, follow-up care, and changes in your condition.
    • Communications: messages with clinicians or pharmacists about side effects, warnings, or medication concerns.

    We also ask about records from before the suspected injury. Earlier notes may help us understand your baseline health and distinguish an existing condition from a new complaint. We do not want you to select only documents that seem favorable to a medication-related explanation; a useful review considers information pointing in different directions.

    Warnings deserve careful attention, but we would not assume that a current information sheet matches what accompanied an earlier prescription. In evaluating that issue, we consider Brown v. Superior Court (1988) 44 Cal.3d 1049, which limits strict design-defect liability for prescription drugs properly prepared and accompanied by adequate warnings of known or reasonably scientifically knowable dangers.

    We suggest keeping originals intact and making a simple list of missing materials. If you cannot locate a record, tell us where you received treatment or filled the prescription. We can discuss which gaps matter most to the next stage of our review.

    How We Examine Your Symptoms and Treatment Timeline

    We examine the sequence of events without assuming that symptoms appearing after medication use establish a connection. Our timeline begins with your health before treatment, follows the medication’s use, and continues through your symptoms, evaluation, and subsequent care. We compare your recollection with contemporaneous records and identify discrepancies for further investigation.

    For example, you may remember fatigue beginning shortly after a refill, while the diagnosis you are concerned about came much later. We would record those as separate events. We would also ask about dosage changes, other medications, illnesses, and treatment interruptions rather than compress your history into a single injury date.

    We typically organize the timeline around:

    • When the medication was first prescribed and first taken.
    • When the dose, formulation, or manufacturer changed, if known.
    • When symptoms first appeared and when you reported them.
    • When testing or evaluation identified a condition.
    • When anyone first discussed a possible medication-related cause.
    • What happened after treatment changed or ended.

    We keep medical questions separate from legal timing questions. A record documenting symptoms may help us investigate the medical history without resolving causation. Likewise, the date of a diagnosis does not, by itself, answer every question about a filing deadline.

    We review timing early because CCP 335.1 provides a two-year limitation period for an action involving injury or death caused by another’s wrongful act or neglect. The discovery rule can postpone accrual until a person discovers, or has reason to discover, the cause of action, as explained in Norgart v. Upjohn Co. (1999) 21 Cal.4th 383. We would need your circumstances to assess how those principles apply.

    We therefore ask you to preserve dated messages, appointment summaries, and notes about conversations concerning a possible cause. We welcome an imperfect timeline; marking a date as approximate is more helpful than guessing. Our review aims to identify what the records establish and what still requires investigation, not to force your experience into a predetermined explanation.

    How We Evaluate Prescription-Drug Claims Under California Law

    We start with your experience, not with the assumption that a medication caused a legally actionable injury. We want to understand what you took, why it was prescribed, what happened afterward, and what your treating clinicians have said. Those details help us identify the questions that need investigation before we offer an assessment.

    California law distinguishes between different theories of prescription-drug liability. In Brown v. Superior Court (1988) 44 Cal.3d 1049, the California Supreme Court held that a prescription-drug manufacturer is not strictly liable for design defect when the drug was properly prepared and accompanied by adequate warnings of dangers known or reasonably scientifically knowable at distribution. We therefore do not treat an unexpected or serious reaction as sufficient, by itself, to establish a design-defect claim.

    Warnings require a separate examination. Carlin v. Superior Court (1996) 13 Cal.4th 1104 recognizes that a person injured by a prescription drug can state a strict-liability failure-to-warn claim involving known or reasonably scientifically knowable dangerous propensities. In our review, we would investigate the particular risk, the relevant warnings, and the information available when the medication was distributed.

    Our initial questions may include:

    • What is the medication’s exact name, and which manufacturer appears on the packaging?
    • When did you begin taking it, and did the dose change?
    • What warning materials or medication guides do you still have?
    • What injury or diagnosis prompted your concern?
    • What other medications or medical conditions appear in your treatment history?

    For example, if symptoms began after a dosage change, we would examine that sequence alongside the medical records rather than assume the timing proves causation. We would also distinguish your recollection from findings documented by your clinicians.

    Our goal is to identify a supportable California-law theory and the evidence still needed. We keep that assessment separate from the question of whether your circumstances warrant investigation in connection with a particular MDL.

    Why We Review Filing Deadlines Early

    We review dates early because uncertainty about whether you have a claim should not leave the timing question unattended. Even when you are still gathering pharmacy records or trying to understand a diagnosis, we can begin organizing the chronology and identifying information needed for a deadline analysis.

    CCP 335.1 provides a two-year limitations period for an action involving injury to, or death of, an individual caused by another’s wrongful act or neglect. We do not simply count two years from your most recent appointment, the date you saw an advertisement, or the day you contacted our office. We first examine the facts relevant to when your claim accrued.

    The discovery rule can matter in that analysis. Norgart v. Upjohn Co. (1999) 21 Cal.4th 383 explains that this rule postpones accrual until a person discovers, or has reason to discover, the cause of action—meaning the person at least suspects, or has reason to suspect, a factual basis for its elements. We would examine what you knew and when, rather than assume that a later diagnosis necessarily supplies the starting date.

    To help us evaluate that issue, we ask you to identify:

    • When you first used the medication and when you stopped.
    • When symptoms first appeared or materially changed.
    • When you received a diagnosis or relevant test result.
    • When anyone first discussed a possible medication-related injury with you.
    • When you first suspected a connection, and what prompted that concern.

    For example, you might remember an earlier conversation about a possible reaction but have received a more definite diagnosis later. We would want both dates and the corresponding records. We would not choose the later date merely because it seems clearer.

    We also ask you to share any existing legal correspondence or filing documents promptly. Our practical recommendation is to contact us while you gather records, rather than wait until your file feels complete. We can identify missing information without treating an incomplete timeline as a final deadline assessment.

    What an Initial Review Can—and Cannot—Tell You

    We view an initial review as a way to replace a broad concern with specific questions. You may come to us knowing only that you took a medication mentioned in litigation and later developed a health problem. We can listen to that history, identify the available documents, and explain what we would need to investigate before reaching a more developed assessment.

    At this stage, we may be able to identify the medication and manufacturer, organize the treatment timeline, flag missing records, and recognize issues requiring prompt attention. We can also discuss whether the information you have provided gives us a reason to investigate further. These are useful steps even when we cannot yet tell you whether your circumstances fit a particular proceeding.

    Our California-law review includes distinguishing a possible warning claim from a design-defect theory. That distinction reflects Carlin v. Superior Court (1996) 13 Cal.4th 1104, which recognizes prescription-drug failure-to-warn claims involving known or reasonably scientifically knowable risks, and Brown v. Superior Court (1988) 44 Cal.3d 1049, which limits prescription-drug strict design-defect liability under the conditions discussed above.

    We would not turn an intake conversation into a definitive statement about medical causation, liability, or an outcome. Nor would we confirm that your circumstances fit a named MDL without examining the relevant proceeding and its current documents. A medication name and a description of symptoms are starting points for that investigation, not substitutes for it.

    We aim to leave you with a practical explanation of:

    • What we understand from the information you supplied.
    • Which facts remain uncertain or need corroboration.
    • Which records would help answer the unresolved questions.
    • Whether we need additional legal research or medical review.
    • What next steps our office proposes.

    We also welcome corrections. If a pharmacy record identifies a different manufacturer than you remembered, or a treatment note changes the chronology, we would reassess rather than force the facts into our initial impression. An honest preliminary review makes room for both supporting and conflicting information.

    How to Prepare for a Free Consultation With Our Office

    We do not expect you to arrive with a legal theory or a perfectly organized medical file. For a consultation with our office, a short account of your concern and whatever records are readily available can give us a useful starting point. If you are unsure whether a document matters, we would rather discuss it than have you struggle to make that judgment alone.

    We suggest preparing a one-page timeline. Include approximate dates when exact dates are unavailable, and mark those estimates clearly. We want to distinguish what you remember from what a prescription label, portal message, or treatment note confirms.

    Helpful materials for our review include:

    • Medication identification: Prescription labels, packaging photographs, medication guides, and pharmacy dispensing histories showing the drug and manufacturer.
    • Treatment information: Relevant visit summaries, diagnoses, test results, and messages discussing your symptoms or a possible medication reaction.
    • Your chronology: Dates of use, dose changes, symptom onset, treatment, and conversations about a possible connection.
    • Litigation information: The name of any MDL you have heard about, along with the article, letter, or other material that prompted your inquiry.
    • Existing documents: Any correspondence with another lawyer or documents concerning a claim already filed.

    We also encourage you to write down how the health problem has affected daily activities, work, sleep, and ongoing treatment. Specific observations are more useful to our review than conclusions about who must be responsible. We would also like to know about other medications and preexisting conditions so that our assessment does not overlook relevant context.

    Bring your questions as well. We can discuss what information is missing, what our office would investigate next, and what remains too uncertain to assess. We ask you not to delay contacting us solely because some records are unavailable.

    You pay nothing unless we win. Fee details are discussed in person during your free consultation.

    To discuss your concerns with Law Offices of Ronald B. Laba, APC, call (760) 940-6231. We can begin with what you know now and explain the additional information we would need for a meaningful review.

    Frequently asked questions

    What if my doctor has not said that the medication caused my condition?

    We can discuss your concerns without asking you to supply a medical conclusion that your doctor has not made. We would want to know what your clinicians actually documented, what testing occurred, and whether they discussed other explanations for your condition. We would keep your observations separate from medical findings. For example, noticing symptoms after starting a medication gives us a sequence to investigate, but we would not treat that sequence alone as proof of a connection. We also would not recommend changing treatment to support a legal inquiry. Questions about continuing, stopping, or replacing medication belong with your treating clinician. Our initial task is to identify unanswered questions and available documentation, not to substitute our judgment for medical care or promise that further review will establish a claim.

    Does a warning on the medication label mean there is no reason to seek a review?

    We would not end our inquiry merely because a label contains some warnings. We would want to examine the warning relevant to your alleged injury and the version accompanying the medication during the period at issue. Carlin v. Superior Court (1996) 13 Cal.4th 1104 recognizes that an injured prescription-drug user can state a strict-liability failure-to-warn claim involving known or reasonably scientifically knowable dangerous propensities. Brown v. Superior Court (1988) 44 Cal.3d 1049 also makes adequate warnings important to its prescription-drug strict-liability analysis. These decisions do not mean that every disputed warning supports a claim. We would investigate the particular risk and the available evidence rather than infer liability from an unpleasant outcome. Keeping the original packaging and inserts, if available, can help us examine the materials you actually received.

    Is it worth calling if I stopped taking the medication years ago?

    We would encourage you to discuss the dates rather than assume that an older prescription makes review pointless. CCP 335.1 provides a two-year limitations period for an action for personal injury caused by another’s wrongful act or neglect. The starting point can require careful analysis. Norgart v. Upjohn Co. (1999) 21 Cal.4th 383 explains that the discovery rule postpones accrual until a person discovers, or has reason to discover, the cause of action, including suspicion of a factual basis for its elements. We would ask when symptoms appeared, when you learned of the diagnosis, and when you first suspected a connection to possible wrongdoing. We cannot calculate a reliable deadline from the last prescription date alone. We also would not assume that recently seeing an advertisement starts a new filing period.

    Should I wait until I have finished treatment before contacting your office?

    We would prefer to discuss your concerns while treatment is ongoing rather than have you postpone an inquiry solely to obtain a complete medical picture. CCP 335.1 establishes a two-year limitations period for personal-injury actions based on another’s wrongful act or neglect. Norgart v. Upjohn Co. (1999) 21 Cal.4th 383 explains the discovery rule in terms of discovering, or having reason to discover, the cause of action. We therefore would not use the end of treatment as our assumed starting date. We can review the information currently available, note what remains uncertain, and revisit medical developments as documentation becomes available. Our office can discuss your questions during a free consultation at (760) 940-6231. We would keep any preliminary assessment separate from a final conclusion about a claim or a particular proceeding.

    Can you review my concerns if I took several medications at the same time?

    We can discuss a possible claim even when your treatment involved multiple medications. We would ask for the full medication history rather than focus only on the product mentioned in an advertisement or news story. Our questions might include which medicines overlapped, whether doses changed, and whether symptoms began before or after those changes. We would also ask about supplements and relevant preexisting conditions so that our review does not overlook other possible explanations. This is an information-gathering approach, not a conclusion about which substance caused an injury. We would avoid asking you to choose a responsible manufacturer based on timing alone. If the records leave important questions unresolved, we would explain those gaps and discuss what further investigation might be useful before assessing a potential California prescription-drug claim.

    Does a serious side effect automatically mean the manufacturer is responsible?

    We would not treat the seriousness of a side effect as an automatic finding of manufacturer responsibility. California prescription-drug law requires a more focused analysis. Brown v. Superior Court (1988) 44 Cal.3d 1049 holds that a manufacturer is not strictly liable for prescription-drug design defects when the drug was properly prepared and accompanied by adequate warnings about dangers known or reasonably scientifically knowable at distribution. Carlin v. Superior Court (1996) 13 Cal.4th 1104 recognizes a strict-liability failure-to-warn claim involving known or reasonably scientifically knowable risks. We therefore look beyond how upsetting or severe the experience was and investigate the medication, the alleged warning problem, and the claimed injury. Those decisions help frame our California-law review; they do not establish eligibility for any particular MDL.

    Should I contact your office if I cannot remember the medication’s exact name?

    We can begin a conversation even if you remember only part of the name or what the medication was prescribed to treat. We would ask you to distinguish what you remember from what you are unsure about rather than guess. A photograph of the container, a pharmacy account entry, or a message from your prescriber may help us identify the product. We would also want to know whether you used more than one version of the medication over time. Identifying the actual product is an investigative step, not a finding that it caused an injury or that a particular proceeding covers your circumstances. We can discuss which records might resolve the uncertainty before offering an assessment of a possible California prescription-drug claim.

    Related questions

    Talk with our office

    Call (760) 940-6231 or send us a message for a free consultation. Learn more on our practice page, browse our learning center.

    Free Case Review

    Get your case evaluated at no cost

    No Win, No Fee
    5.0 Rating

    By submitting this form, you consent to be contacted by our law firm. Your information is confidential and protected.

    Prefer to talk?

    (760) 940-6231
    No Fee Unless We Win
    100% Contingency
    5,000+ Cases
    Successfully Handled
    Free Consultation
    Available 24/7
    Practicing Since 1984
    Experience
    Client Reviews

    What Our Clients Say

    Real testimonials from successful cases

    5.0

    "I wanted to take a moment to sincerely thank you for everything you did to..."

    Israel & April Romanabout 2 months ago
    Verified
    5.0

    "The Law office of Ronald B. Laba have helped me navigate the justice system through..."

    Anthony Hanna11 months ago
    Contact Us

    Get Your Free Consultation

    Don't wait to get the legal help you need. Contact us today for a free, no-obligation consultation about your personal injury case.

    Free Case Evaluation

    Get your case reviewed by an experienced attorney at no cost

    By submitting this form, you consent to be contacted by our law firm. Your information is confidential and protected.